Clinical trial NCT00633321 - References

Smoking — Study of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation

Citation(s)

•   Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C, Rose JE
  Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res. 2001 May;3(2):101-9. Review.
•   Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG
  Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. Addict Behav. 2007 May;32(5):912-23. Epub 2006 Jul 27.
•   Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG
  Confirmatory validation of the Brief Questionnaire of Smoking Urges. Value in Health 2005;8(3):334.
•   CDC
  National Center for Health Statistics: Health, United States, 2004 With Chartbook on Trends in the Health of Americans. Hyattsville, MD: U.S. Department of Health and Human Services, CDC, 2004.
•   CDC
  Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, CDC, Office on Smoking and Health; 2000.
•   CDC
  The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General 1988. Rockville, MD: U.S. Department of Health and Human Services, CDC, Center for Health Promotion and Education, Office on Smoking and Health; 1988.
•   Centers for Disease Control and Prevention (CDC)
  Annual smoking-attributable mortality, years of potential life lost, and economic costs--United States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002 Apr 12;51(14):300-3.
•   Centers for Disease Control and Prevention (CDC)
  Annual smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 1997-2001. MMWR Morb Mortal Wkly Rep. 2005 Jul 1;54(25):625-8.
•   Centers for Disease Control and Prevention (CDC)
  Cigarette smoking among adults--United States, 1994. MMWR Morb Mortal Wkly Rep. 1996 Jul 12;45(27):588-90.
•   Centers for Disease Control and Prevention (CDC)
  Cigarette smoking among adults--United States, 2000. MMWR Morb Mortal Wkly Rep. 2002 Jul 26;51(29):642-5.
•   Centers for Disease Control and Prevention (CDC)
  Tobacco use among adults--United States, 2005. MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8.
•   Cox LS, Tiffany ST, Christen AG
  Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001 Feb;3(1):7-16.
•   Doll R, Hill AB
  The mortality of doctors in relation to their smoking habits: a preliminary report. 1954. BMJ. 2004 Jun 26;328(7455):1529-33; discussion 1533.
•   Fagerstrom KO, Schneider NG
  Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989 Apr;12(2):159-82. Review.
•   Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al
  Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service; 2000.
•   Fiore MC, Bailey WC, Cohen SJ, et al
  Smoking cessation. Clinical Practice Guideline No 18. Rockville, Maryland: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, April 1996. (AHCPR Publication No 96-0692).
•   Hall SM, Humfleet GL, Reus VI, Muñoz RF, Hartz DT, Maude-Griffin R
  Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry. 2002 Oct;59(10):930-6.
•   Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston JA, White JD
  Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med. 2001 Sep 18;135(6):423-33.
•   Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO
  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.
•   Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR
  Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol. 2000 Oct;22(10):809-19.
•   Hieda Y, Keyler DE, VanDeVoort JT, Niedbala RS, Raphael DE, Ross CA, Pentel PR
  Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berl). 1999 Apr;143(2):150-7.
•   Hughes JR, Stead LF, Lancaster T
  Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD000031.
•   Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM
  A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997 Oct 23;337(17):1195-202.
•   Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB
  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999 Mar 4;340(9):685-91.
•   Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T
  Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend. 1994 Feb;34(3):211-6.
•   Malin DH, Lake JR, Lin A, Saldaña M, Balch L, Irvin ML, Chandrasekara H, Alvarado CL, Hieda Y, Keyler DE, Pentel PR, Ennifar S, Basham LE, Naso R, Fattom A
  Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav. 2001 Jan;68(1):87-92.
•   Pentel PR, Malin DH, Ennifar S, Hieda Y, Keyler DE, Lake JR, Milstein JR, Basham LE, Coy RT, Moon JW, Naso R, Fattom A
  A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav. 2000 Jan 1;65(1):191-8.
•   Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV
  Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther. 1994 Jul;56(1):86-99.
•   Rose JE, Behm FM, Westman EC
  Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol. 1998 Aug;6(3):331-43.
•   Silagy C, Lancaster T, Stead L, Mant D, Fowler G
  Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD000146.
•   Silagy C, Mant D, Fowler G, Lodge M
  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet. 1994 Jan 15;343(8890):139-42.
•   USDHHS
  The health consequences of smoking: nicotine addiction. Rockville, Maryland: Office on Smoking and Health, 1988.
•   West RJ, Russell MA
  Cardiovascular and subjective effects of smoking before and after 24 h of abstinence from cigarettes. Psychopharmacology (Berl). 1987;92(1):118-21.
•   Westman, E
  C., Levin, E. D., & Rose, J. E. Smoking while wearing the nicotine patch: Is smoking satisfying or harmful? Clinical Research. 1992;40, 871A.
•   World Health Organization; Tobacco Free Initiative: Why is tobacco a public health priority? http:www
  who.int/tobacco/en

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study of 100 or 250 μg of TA-NIC to Assess the Efficacy and Safety of the Vaccine as an Aid to Smoking Cessation

Details for clinical trial NCT00633321